All-BARI-RA Updated Findings: Long-term Safety of Baricitinib in Patients With Rheumatoid Arthritis

Pooled analysis of filgotinib trials in rheumatoid arthritis presented at ACR 2020 finds low incidence of VTE and MACE regardless of dose, by CCO

ACR 2020: ARCTIC REWIND on flare risk of TNF inhibitor taper and withdrawal among patients with rheumatoid arthritis (RA) and stable remission, as reported by CCO

CCO highlights from Stanley Cohen, Sheetal Desai, Eric Ruderman on JAKs before and after DMARD failure, treat-to-target, shared decision making

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: November 13, 2020

ACR 2020: SEAM-RA trial on switch to ETN or MTX monotherapy vs continued combination therapy in RA patients with stable remission, as reported by CCO